Recombinant Canine TrkA Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-4651
Recombinant Canine TrkA Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-4651
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | Fc |
Host Species | Canine |
Accession | XP_851619.3 |
Background | TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
Description | A DNA sequence encoding the canine NTRK1 (XP_851619.3) (Pro285-Lys410) was expressed with the Fc region of human IgG1 at the N-terminus. |
Source | HEK293 |
Predicted N Terminal | Glu |
AA Sequence | Pro285-Lys410 |
Molecular Weight | The recombinant canine NTRK1/Fc is a disulfide-linked homodimer. The reduced monomer comprises 386 a.a. and has a predicted molecular mass of 42.3 kDa. The apparent molecular mass of the protein is approximately 55-61 kDa in SDS-PAGE under reducing conditions. |
Purity | >90% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | Measured by its ability to inhibit NGF-induced proliferation of TF-1 human erythroleukemic cells.The ED50 for this effect is typically 2-8 µg/mL in the presence of 10 ng/mL of recombinant human NGF. |
Formulation | Lyophilized from sterile PBS, pH 7.4.. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |